Справка
x
Поиск
Закладки
Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Себорейный дерматит
Список литературы
Поставить закладку
Clark GW, Pope SM, Jaboori KA Diagnosis and treatment of seborrheic dermatitis. AmFamPhysician. 2015 Feb 1; 91(3):185-90.
Schwartz JR, Messenger AG, Tosti A, Todd G, Hordinsky M, Hay RJ, Wang X, Zachariae C, Kerr KM, Henry JP, Rust RC, Robinson MK comprehensive pathophysiology of dandruff and seborrheic dermatitis - towards a more precise definition of scalp health. ActaDermVenereol. 2013 Mar 27; 93(2):131-7.
Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006;74(1):125–30.
Choeng WK, Yeung CK, Torsekar RG, Suh DH, Ungpakorn R, Widaty S, et al. Treatment of seborrhoeic dermatitis in Asia: a consensus guide. Skin Appendage Disord. 2015;1:187–96
Chatzikokkinou P, Sotiropoulos K, Katoulis A, Luzzati R, Trevisan G. Seborrheic dermatitis—an early and common skin manifestation in HIV patients. ActaDermatovenerolCroat ADC. 2008;16(4):226–30.
Cribier B, Samain F, Vetter D, Heid E, Grosshans E. Systematic cutaneous examination in hepatitis C virus infected patients. ActaDermVenereol. 1998;78(5):355–7.20.
Barba A, Piubello W, Vantini I, Caliari S, Cocchetto R, Vallaperta P, et al. Skinlesionsinchronicalcoholicpancreatitis. Dermatologica. 1982;164(5):322–6.
BukvićMokos Z, Kralj M, Basta-Juzbašić A, LakošJukić I Seborrheic dermatitis: an update. ActaDermatovenerol Croat. 2012; 20(2):98-104.
Clark GW, Pope SM, Jaboori KA Diagnosis and treatment of seborrheic dermatitis. AmFamPhysician. 2015 Feb 1; 91(3):185-90.
Sampaio AL, Mameri AC, Vargas TJ, Ramos-e-Silva M, Nunes AP, Carneiro SC Seborrheic dermatitis. AnBrasDermatol. 2011 Nov-Dec; 86(6):1061-71; quiz 1072-4.
Renee Howard Leiner's syndrome: Erythroderma, diarrhea, and failure to thrive Current Problems in Dermatology Volume 12, Issue 4, July–August 2000, Pages 183-185
Hald M, Arendrup MC, Svejgaard EL, Lindskov R, Foged EK, et al. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. ActaDermVenereol. 2015;95:12–19
Gupta AK, Richardson M, Paquet M: Systematic review of oral treatments for seborrheic dermatitis. J EurAcadDermatolVenereol 2014;28:16-26.
Kim GW, Jung HJ, Ko HC, et al. Dermoscopy can be useful in differentiating scalp psoriasis from seborrheic dermatitis. Br J Dermatol. 2011;164(3):652–656.
MelikeKibar, Şebnem Aktan,1 and MuzafferBilginDermoscopic Findings in Scalp Psoriasis and Seborrheic Dermatitis; Two New Signs; Signet Ring Vessel and Hidden Hair Indian J Dermatol. 2015 Jan-Feb; 60(1): 41–45.
SezinFicicioglu, SuleymanPiskinDermoscopic findings in psoriasis and seborrheic dermatitis on the scalp and correlation with disease severity Medicine Science 2018;7(1):118-21
Abbas Z, Ghodsi SZ, Abedeni R. Effect of itraconazole on the quality of life in patients with moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial. DermatolPract Concept. 2016;6(3):11–6.
Apasrawirote W1, Udompataikul M, RattanamongkolgulS Topical antifungal agents for seborrheic dermatitis: systematic review and meta-analysis. J Med Assoc Thai. 2011 Jun;94(6):756-60.
Pierard-Franchimont C, Goffin V, Decroix J, Pierard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin PharmacolAppl Skin Physiol. 2002;15:434–441.
Ratnavel RC, Squire RA, Boorman GC. Clinical efficaciesof shampoos containing ciclopiroxolamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat 2007; 18: 88–96.
Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopiroxolamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatol Treat 2002; 13: 51–60.
Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev. 2015;5
Mohamad Goldust, ElhamRezaee, Shahin Rouhani. Double blind study of sertaconazole 2% cream vs. clotrimazole 1% cream in treatment of seborrheic dermatitis. AnnalsofParasitology 2013, 59(1), 25–29
Pierard-Franchimont C, Goffin V, Decroix J, Pierard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin PharmacolAppl Skin Physiol. 2002;15:434–441
Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am AcadDermatol 1993; 29: 1008–1012.
Gilbertson K, Jarrett R, Bayliss SJ, Berk DR. Scalp discoloration from selenium sulfide shampoo: a case series and review of the literature. PediatrDermatol. 2012;29:84–88
Juan Jorge Manríquez and Pablo Uribe Seborrhoeic dermatitis BMJ ClinEvid. 2007; 2007: 1713.
Davies DB, Boorman GC, Shuttleworth D. Comparative efficacy of shampoos containing coal tar (4.0% w/w; Tarmed™), coal tar (4.0% w/w) plus ciclopirox olamine (1.0% w/w; Tarmed™ AF) and ketoconazole (2.0% w/w; Nizoral™) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatolog Treat. 2009;10:177–183
Ortonne JP, Nikkels AF, Reich K, Ponce Olivera RM, Lee JH, Kerrouche N, et al. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: A randomized, controlled study. Br J Dermatol. 2011;165:171–6. doi: 10.1111/j.1365- 2133.2011.10269.x
Chattopadhyay SP, Arora PN, Anand S, Sharma SD Betamethasone dipropionate (0.05%) plus salicylic acid (3%) ointment versus dexamethasone trimethyl acetate (1%) and salicylic acid 4% ointments in chronic dermatoses. Indian J Dermatol. 1987 Apr;32(2):41-4.
Nolting S, Hagemeier HH. [Therapy of erythrosquamous dermatoses. Betamethasone dipropionate plus salicylic acid in comparison with betamethasone dipropionate solution]. Fortschr Med. 1983 Oct 6;101(37):1679-83
Шеклакова М.Н Оценка эффективности применения нового препарата пиритиона цинка Цинокап® в терапии больных себорейным дерматитом Vestn DermatolVenerol 2010; 3: 49–55
Opdyke DL, Burnett CM, Brauer EW anti-seborrhoeic qualities of zinc pyrithione in a cream vehicle. II. Safety evaluation. Food CosmetToxicol. 1967 Aug; 5(3):321-6.
Papp KA, Papp A, Dahmer B, Clark CS Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults.J Am AcadDermatol. 2012 Jul; 67(1):e11-5.c
Kastarinen H, Oksanen T, Okokon EO, Kiviniemi VV, Airola K, Jyrkka¨ J, et al. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp. Cochrane Database Syst Rev.2014;5
Medansky R, Lepaw M, Shavin J, Zimmerman E, Jones M, Peets E, et al. Mometasonefuroate cream 0.1 % vs. hydrocortisone cream 1 % in the treatment of seborrheic dermatitis. J Dermatol Treat. 1992;3:125–8.
Milani M1, Antonio Di Molfetta S, Gramazio R, Fiorella C, Frisario C, Fuzio E, Marzocca V, Zurilli M, Di Turi G, Felice G Efficacy of betamethasone valerate 0.1% thermophobic foam in seborrhoeic dermatitis of the scalp: an open-label, multicentre, prospective trial on 180 patients. Curr Med Res Opin. 2003;19(4):342-5.
Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol. 2004 Nov; 151(5):1071-5.
Cicek D1, Kandi B, Bakar S, Turgut D. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatolog Treat. 2009;20(6):344-9.
Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, et al. Results of a randomized, double-blind, vehicle controlled efficacy trial of pimecrolimus cream 1 % for the treatment of moderate to severe facial seborrheic dermatitis. J Am AcadDermatol. 2007;57(2):257–64.
Kim T-W, Mun J-H, Wa S-WJ, Song M, Kim H-S, Ko H-C, et al. Proactive treatment of adult facial seborrheic dermatitis with 0.1 % tacrolimus ointment: randomized, double-blind, vehicle controlled, multi-center trial. ActaDermVenereol. 2013;93:557–61.
Unholzer A, Schinzel S, Nietsch K-H, Jung GE, Korting HC. Ciclopiroxolamine cream 1 % in the treatment of seborrheic dermatitis: a double-blind, parallel-group comparison with ketoconazole and vehicle in a confirmatory trial. Clin Drug Invest. 2002;22(3):167–72.
Aditya K. Gupta, Sarah G. VersteegTopical Treatment of Facial Seborrheic Dermatitis: A SystematicReviewAm J ClinDermatol2017 Apr;18(2):193-213
Pirkhammer D., Seeber A., Honigsmann H., Tanew A. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000; №143 (5): 964–968.
Gupta AK, Richardson M, Paquet M: Systematic review of oral treatments for seborrheic dermatitis. J EurAcadDermatolVenereol 2014;28:16-26.
Ghodsi SZ, Abbas Z, Abedeni R. Efficacy of oral itraconazole in the treatment and relapse prevention of moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial. Am J ClinDermatol. 2015; №16 (5): 431–437.
Scaparro E., Quadri G., Virno G. et al. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil®) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol 2001; №144 (4): 854–857.
Cömert A., Bekiroglu N., Gürbüz O., Ergun T. Efficacy of oral fluconazole in the treatment of seborrheic dermatitis: a placebo-controlled study. Am J ClinDermatol 2007; №8 (4): 235–238.
Gupta AK, Bluhm R. Seborrheic dermatitis. J EurAcadDermatolVenereol. 2004;18:13–26.
Victoire A, Magin P, Coughlan J, van Driel ML Treatments for infantile seborrhoeic dermatitis (including cradle cap), an inflammatory, scaly skin condition Cochrane Systematic Review - Intervention Version published: 04 March 2019
Elish D, Silverberg NB. Infantile seborrheic dermatitis. Cutis 2006;77(5):297‐300 Nobles T, Krishnamurthy K. Cradle Cap. SourceStatPearls Treasure Island (FL): StatPearls Publishing; 2019-.2019 Jan 23.
Wannanukul S1, ChiabunkanaJ.Comparative study of 2% ketoconazole cream and 1% hydrocortisone cream in the treatment of infantile seborrheic dermatitis J Med Assoc Thai. 2004 Sep;87Suppl 2:S68-71.
Taieb A, Legrain V, Palmier C, Lejean S, Six M, Maleville J. Topical ketoconazole for infantile seborrhoeic dermatitis. Dermatologica 1990; 181: 26–32
Hald M, Arendrup MC, Svejgaard EL, Lindskov R, Foged EK, et al. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. ActaDermVenereol. 2015;95:12–19
Sauer, Gordon C.; Hall, John C. (1996). "Leiner's Disease". Manual of Skin Diseases (7th ed.).
Ann Dermatol. 2016 Aug; 28(4): 427–432 Ji-Hye Park, Young Joon Park, [...], and You Chan Kim Histopathological Differential Diagnosis of Psoriasis and Seborrheic Dermatitis of the Scalp
Для продолжения работы требуется
Регистрация
Предыдущая страница
Следующая страница
Оглавление
Список сокращений
Термины и определения
Себорейный дерматит
+
Список литературы
Приложение А1. Состав рабочей группы по разработке и пересмотру клинических рекомендаций
Приложение А2. Методология разработки клинических рекомендаций
Приложение А3. Справочные материалы, включая соответствие показаний к применению и противопоказаний, способов применения и доз лекарственных препаратов, инструкции по применению лекарственного препарата
Приложение Б. Алгоритмы действий врача
Приложение В. Информация для пациента
Приложение Г1-ГN. Шкалы оценки, вопросники и другие оценочные инструменты состояния пациента, приведенные в клинических рекомендациях
Данный блок поддерживает скрол*